Low Intensity Laser Therapy on Immune System Response Among Children With Pneumonia
ConditionPneumonia
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age3-5
SponsorBadr University
About this trial
Objective: The aim of this study was to detect the impact of low intensity laser therapy on immune system response among DS children with pneumonia. Material and Methods: Forty DS children with bronchopneumonia, were included into ; group (A) received low intensity laser therapy, inspiratory muscle training in addition to medical treatment at a frequency of 3 sessions per week for one month, where the second group (B) received inspiratory muscle training in addition to medical treatment. Measurements of WBCs, IgG, IgA, IgM, RR and SaO2 were obtained for both groups before treatment and after one month at the end of the treatment program.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Dawn Syndrome children with pneumonia
Mean age of 3.73±1.82 year
Children were in the first attack of bronchopneumonia.
Disqualifiers
Other chest disease
Trial design
Design model
Parallel
Treatments tested in this trial
low intensity laser therapy ,muscle training using incentive spirometer associated with postural drainage in addition to medical treatment. Measurements
Other interventionlow intensity laser therapy ,muscle training using incentive spirometer associated with postural drainage in addition to medical treatment. Measurements
received inspiratory muscle training using incentive spirometer associated with postural drainage in addition to medical treatment.
Other interventionreceived inspiratory muscle training using incentive spirometer associated with postural drainage in addition to medical treatment.
Treatment groups
40 Participants
are divided into 2 treatment groupsGroup A: group (A)Experimental treatment 2 interventions
Group B: group (B)Experimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
IgG
Immunoglobulin-G (mg/dl)
Time frame
at baseline and after one month2
IgA
Immunoglobulin-A(mg/dl)
Time frame
at baseline and after one month3
IgM
Immunoglobulin-M (mg/dl)
Time frame
at baseline and after one month4
WBCs
White blood cells (thousands/mm3)
Time frame
at baseline and after one monthSecondary outcomes
1
RR
Respiratory Rate(breath/minute)
Time frame
at baseline and after one month2
SaO2
Arterial oxygen saturation(%)
Time frame
at baseline and after one monthSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov